A Clinical Prospective Study of Chemotherapy-Induced Mucocutaneous Adverse Effects in Cancer Patients

Authors

  •   K. R. Tharanee Dermatology, Venereology and Leprosy, Coimbatore Medical College, Coimbatore – 641014, Tamil Nadu
  •   Eswaramurthi Dermatology, Venereology and Leprosy, Coimbatore Medical College, Coimbatore – 641014, Tamil Nadu
  •   Revathy Dermatology, Venereology and Leprosy, Coimbatore Medical College, Coimbatore – 641014, Tamil Nadu

DOI:

https://doi.org/10.65129/medical.v1i1.28

Keywords:

Anagen Effluvium, Chemotherapy, Cutaneous Extravasation, Facial Hyperpigmentation, Hyperpigmentation, Melanonychia, Onycholysis, Supravenous

Abstract

Chemotherapy remains the mainstay of cancer management but is frequently accompanied by diverse mucocutaneous adverse effects due to its action on rapidly proliferating cells. These toxicities can range from mild cosmetic issues to severe reactions necessitating dose modification or discontinuation. This prospective observational study conducted at the Department of Dermatology, Government Coimbatore Medical College, systematically evaluated the prevalence, pattern, timing, and drug associations of mucocutaneous adverse reactions among 30 adult patients undergoing single or combination chemotherapy regimens over one year. Nail changes (73.3%), hair changes (50%), mucosal changes (10%) and cutaneous changes (63.3%) were the most common adverse effects, with higher rates than comparable studies like Pavey et al. Specific skin changes noted were xerosis, hand and foot syndrome, cutaneous extravasation, facial hyperpigmentation and supravenous hyperpigmentation. Specific nail changes were onycholysis and melanonychia. Hair changes included anagen effluvium, and mucosal changes included mucosal pigmentation. Early-onset reactions within the first 2-4 cycles were frequent. Proactive counselling, dermatological management, and patient education were effective in minimising morbidity and ensuring uninterrupted therapy. The study highlights the critical role of dermatology-oncology collaboration in holistic cancer care.

Downloads

Download data is not yet available.

Downloads

Published

2025-03-30

How to Cite

Tharanee, K. R., Eswaramurthi, & Revathy. (2025). A Clinical Prospective Study of Chemotherapy-Induced Mucocutaneous Adverse Effects in Cancer Patients. Journal of Medical and Medical Specialities, 1(1), 1–10. https://doi.org/10.65129/medical.v1i1.28

Issue

Section

Research Article

References

1. Naveed S, Thappa D, Dubashi B, Pandjatcharam J, Munisamy M, Singh N. Mucocutaneous adverse effects of chemotherapy and chemoradiation in cancer patients: A prospective study in a tertiary care center. Indian J Dermatol. 2019; 64(2):122-127. https://doi.org/10.4103/ijd.IJD_129_17 PMid:30983608 PMCid:PMC6440193

2. Pavey RA, Kambil SM, Ganguly S. Chemotherapyinduced mucocutaneous manifestations: A crosssectional study of 200 patients. Indian J Dermatol. 2015; 60(5):419-425.

3. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous side effects of chemotherapy. Clin Dermatol. 1999; 17(4):391-400.

4. Sekine I, Sumi M, Ito Y, et al. Incidence and risk factors for hand-foot syndrome in Japanese patients receiving capecitabine chemotherapy. Jpn J Clin Oncol. 2012; 42(10):849-854.

5. Hofheinz RD, Deplanque G, Komatsu Y, et al. Recommendations for the prophylaxis and management of hand-foot syndrome in patients receiving capecitabine and similar agents. ESMO Open. 2015; 26(3):1-9.

6. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6(10):803812. https://doi.org/10.1038/nrc1970 PMid:16990857

7. Sibaud V. Dermatological complications of novel targeted anti-cancer therapies. J Eur Acad Dermatol Venereol. 2016; 30(8):1421-1430.

8. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier; 2018.

9. Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004; 2(6 Suppl 3):3-8. https://doi.org/10.1038/ncponc0104 PMid:16264905

10. Langer CJ, Patel JD, Soo RA. Cutaneous toxicities of EGFR inhibitors: Pathophysiology and management. Oncologist. 2020; 25(1):e30-e40.

11. Saif MW, Sandoval A, Syrigos K. Hand-foot syndrome associated with capecitabine and cytarabine: Review and recommendations. J Oncol Pharm Pract. 2019; 25(3):686-692.

12. Schulmeister L, Quillen JM, Camp-Sorrell D. Chemotherapy extravasation: Prevention and management guidelines. Eur J Oncol Nurs. 2018; 34: 7-12.

13. Ho W, Balaban M, Tey HL. Serpentine supravenous hyperpigmentation: Clinical clues and practical approach. Dermatol Online J. 2017; 23(12):1-6.

14. Ockenfels HM, Schramm M, Zillikens D. Imatinibinduced pigmentary disorders: A case series. J Dtsch Dermatol Ges. 2020; 18(6):577-583.

15. Sekulic A, Hudson J, Kerr PE. Taxane-induced nail changes: A comprehensive review. Support Care Cancer. 2017; 25(7):2157-2162.

16. Demirkan NC, Gür Ö, Yücel A. Capecitabine-induced melanonychia: Clinical and dermoscopic features. Clin Exp Dermatol. 2016; 41(2):220-223.

17. Trüeb RM. Chemotherapy-induced alopecia: Pathogenesis and management. Dermatology. 2009; 219(3):203-210.

18. Gambichler T, Boms S, Stücker M. Oral mucosal pigmentation associated with hydroxyurea: A clinical observation. Clin Exp Dermatol. 2015; 40(3):313-316.

Similar Articles

You may also start an advanced similarity search for this article.